NASDAQ:QTRX Quanterix (QTRX) Stock Forecast, Price & News $23.09 +0.58 (+2.58%) (As of 02:46 PM ET) Add Compare Share Share Today's Range$22.16▼$23.2350-Day Range$10.85▼$22.5152-Week Range$6.31▼$23.44Volume145,815 shsAverage Volume332,782 shsMarket Capitalization$863.80 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Quanterix MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside21.3% Downside$18.00 Price TargetShort InterestHealthy2.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.19) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.02 out of 5 starsMedical Sector960th out of 981 stocksAnalytical Instruments Industry27th out of 27 stocks 1.1 Analyst's Opinion Consensus RatingQuanterix has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, Quanterix has a forecasted downside of 21.3% from its current price of $22.88.Amount of Analyst CoverageQuanterix has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.63% of the float of Quanterix has been sold short.Short Interest Ratio / Days to CoverQuanterix has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quanterix has recently increased by 0.53%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldQuanterix does not currently pay a dividend.Dividend GrowthQuanterix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTRX. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Quanterix this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for QTRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quanterix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Quanterix is held by insiders.Percentage Held by Institutions80.60% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Quanterix are expected to grow in the coming year, from ($1.19) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quanterix is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quanterix is -10.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuanterix has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Quanterix (NASDAQ:QTRX) StockQuanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.Read More Receive QTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter. Email Address QTRX Stock News HeadlinesJune 7, 2023 | finance.yahoo.comQuanterix to Participate in Fireside Chat at Goldman Sachs Annual Global Healthcare ConferenceMay 25, 2023 | americanbankingnews.comQuanterix (NASDAQ:QTRX) Stock Rating Upgraded by The Goldman Sachs GroupJune 8, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 24, 2023 | msn.comGoldman Sachs Maintains Quanterix (QTRX) Buy RecommendationMay 24, 2023 | 247wallst.comGoldman Sachs Upgrades QuanterixMay 23, 2023 | msn.comGoldman Sachs Upgrades Quanterix (QTRX)May 23, 2023 | seekingalpha.comQuanterix at one-year high as Goldman upgrades on neuro opportunityMay 23, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For May 23, 2023June 8, 2023 | Behind the Markets (Ad)⚡ 2,467% Return on Israeli Laser Company?This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.May 23, 2023 | msn.comQuanterix at one-year high as Godman upgrades on neuro opportunityMay 23, 2023 | americanbankingnews.comQuanterix Co. (NASDAQ:QTRX) Given Average Rating of "Hold" by AnalystsMay 23, 2023 | markets.businessinsider.comPositive Report for Quanterix (QTRX) from Goldman SachsMay 16, 2023 | finance.yahoo.comShareholders in Quanterix (NASDAQ:QTRX) are in the red if they invested three years agoMay 14, 2023 | americanbankingnews.comQ3 2023 Earnings Forecast for Quanterix Co. (NASDAQ:QTRX) Issued By SVB LeerinkMay 12, 2023 | americanbankingnews.comQuanterix (NASDAQ:QTRX) Sets New 1-Year High at $20.20May 9, 2023 | finance.yahoo.comQuanterix Releases Operating Results for First Quarter 2023May 7, 2023 | americanbankingnews.comQuanterix (QTRX) Set to Announce Quarterly Earnings on TuesdayMay 5, 2023 | americanbankingnews.comQuanterix (NASDAQ:QTRX) Stock Price Up 13%May 4, 2023 | finance.yahoo.comQuanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?May 2, 2023 | finance.yahoo.comQuanterix’s First Quarter 2023 Earnings Conference CallApril 25, 2023 | finance.yahoo.comFDA Accelerated Approval of Tofersen Highlights Importance of Blood Neurofilament Light Chain as Surrogate Endpoint in Neurology Therapeutic TrialsApril 17, 2023 | finance.yahoo.comInvestors Holding Back On Quanterix Corporation (NASDAQ:QTRX)April 14, 2023 | americanbankingnews.comQuanterix (NASDAQ:QTRX) Shares Up 3.7%March 17, 2023 | seekingalpha.comQuanterix (QTRX) presents at Barclays Global Healthcare Conference - SlideshowMarch 14, 2023 | finance.yahoo.comQuanterix to Participate in Barclays Global Healthcare ConferenceMarch 11, 2023 | msn.comQuanterix's Return On Capital Employed InsightsMarch 8, 2023 | finance.yahoo.comQuanterix Corporation (NASDAQ:QTRX) Q4 2022 Earnings Call TranscriptSee More Headlines QTRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTRX Company Calendar Last Earnings5/09/2023Today6/08/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTRX CUSIPN/A CIK1503274 Webwww.quanterix.com Phone(617) 301-9400FaxN/AEmployees460Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$27.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside-20.7%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,700,000.00 Net Margins-81.08% Pretax Margin-80.68% Return on Equity-17.22% Return on Assets-14.32% Debt Debt-to-Equity RatioN/A Current Ratio13.96 Quick Ratio13.32 Sales & Book Value Annual Sales$105.52 million Price / Sales8.04 Cash FlowN/A Price / Cash FlowN/A Book Value$9.69 per share Price / Book2.34Miscellaneous Outstanding Shares37,410,000Free Float34,865,000Market Cap$848.83 million OptionableNot Optionable Beta1.32 Key ExecutivesMasoud TolouePresident, Chief Executive Officer & DirectorDaniel PikoraChief Operating OfficerMichael A. DoyleChief Financial Officer & TreasurerDavid C. DuffyChief Technology Officer & Vice President-ResearchMark T. RoskeyChief Science & Collaboration OfficerKey CompetitorsCytek BiosciencesNASDAQ:CTKBNautilus BiotechnologyNASDAQ:NAUTSeerNASDAQ:SEERBionano GenomicsNASDAQ:BNGOEyePoint PharmaceuticalsNASDAQ:EYPTView All CompetitorsInsiders & InstitutionsRoyce & Associates LPSold 168,200 shares on 5/23/2023Ownership: 0.683%Ameriprise Financial Inc.Bought 172,719 shares on 5/22/2023Ownership: 2.743%JPMorgan Chase & Co.Sold 8,811 shares on 5/18/2023Ownership: 0.356%New York State Common Retirement FundSold 4,086 shares on 5/18/2023Ownership: 0.148%Jane Street Group LLCBought 13,949 shares on 5/16/2023Ownership: 0.037%View All Insider TransactionsView All Institutional Transactions QTRX Stock - Frequently Asked Questions Should I buy or sell Quanterix stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" QTRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTRX, but not buy additional shares or sell existing shares. View QTRX analyst ratings or view top-rated stocks. What is Quanterix's stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year target prices for Quanterix's stock. Their QTRX share price forecasts range from $12.00 to $27.00. On average, they expect the company's stock price to reach $18.00 in the next twelve months. This suggests that the stock has a possible downside of 20.7%. View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts. How have QTRX shares performed in 2023? Quanterix's stock was trading at $13.85 at the beginning of the year. Since then, QTRX stock has increased by 63.8% and is now trading at $22.69. View the best growth stocks for 2023 here. When is Quanterix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our QTRX earnings forecast. How were Quanterix's earnings last quarter? Quanterix Co. (NASDAQ:QTRX) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.20. The firm earned $28.46 million during the quarter, compared to the consensus estimate of $25.46 million. Quanterix had a negative net margin of 81.08% and a negative trailing twelve-month return on equity of 17.22%. What ETFs hold Quanterix's stock? ETFs with the largest weight of Quanterix (NASDAQ:QTRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), What guidance has Quanterix issued on next quarter's earnings? Quanterix issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $104.00 million-$111.00 million, compared to the consensus revenue estimate of $106.71 million. What is Kevin Hrusovsky's approval rating as Quanterix's CEO? 15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees. What other stocks do shareholders of Quanterix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA). When did Quanterix IPO? (QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers. What is Quanterix's stock symbol? Quanterix trades on the NASDAQ under the ticker symbol "QTRX." Who are Quanterix's major shareholders? Quanterix's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.27%), Granahan Investment Management LLC (3.47%), Ameriprise Financial Inc. (2.74%), Deutsche Bank AG (2.64%), Frontier Capital Management Co. LLC (2.62%) and Gilder Gagnon Howe & Co. LLC (2.38%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Martin D Madaus, Masoud Toloue and Michael A Doyle. View institutional ownership trends. How do I buy shares of Quanterix? Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Quanterix's stock price today? One share of QTRX stock can currently be purchased for approximately $22.69. How much money does Quanterix make? Quanterix (NASDAQ:QTRX) has a market capitalization of $848.83 million and generates $105.52 million in revenue each year. The company earns $-96,700,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. How many employees does Quanterix have? The company employs 460 workers across the globe. How can I contact Quanterix? Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The official website for the company is www.quanterix.com. The company can be reached via phone at (617) 301-9400 or via email at ir@quanterix.com. This page (NASDAQ:QTRX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quanterix Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.